Show simple item record

Cost-Effectiveness of once-daily, single-inhaler indacaterol acetate/ glycopyrronium bromide/ mometasone furoate in Patients with uncontrolled moderate-to-severe asthma in Canada

dc.contributor.authorMtibaa, M
dc.contributor.authorGupta, S
dc.contributor.authorMuthukumar, M
dc.contributor.authorMarvel, J
dc.contributor.authorKaur, H
dc.contributor.authorIshikawa, R
dc.contributor.authorOlivenstein, R
dc.date.accessioned2021-12-03T13:51:47Z
dc.date.issued2021-12-03
dc.date.updated2021-12-03T12:25:39Z
dc.description.abstractPurpose: We evaluated the cost-effectiveness of high-dose indacaterol acetate (IND)/glycopyrronium bromide (GLY)/mometasone furoate (MF) (150/50/160 μg, once daily) compared with high-dose salmeterol/fluticasone (SAL/FLU; 50/500 µg, twice daily)+tiotropium (TIO; 5 µg, once daily) (SAL/FLU+TIO) and with high-dose SAL/FLU (50/500 µg, twice daily) for the treatment of inadequately controlled moderate-to-severe asthma. Patients and Methods: A Markov model estimated the incremental cost-effectiveness ratio of treatment with high-dose IND/GLY/MF compared with SAL/FLU+TIO and high-dose IND/GLY/MF compared with SAL/FLU. The model included three health states (day-to-day symptoms without exacerbations, day-to-day symptoms with exacerbations, and death) with a 4-week cycle length. A lifetime time horizon was used. Exacerbation rates and utility values were derived from ARGON and IRIDIUM clinical trials. Canadian dollars (CAD$, 2020) were applied. Results: IND/GLY/MF was the less costly and more effective treatment strategy compared with SAL/FLU+TIO and SAL/FLU in the base-case analyses. IND/GLY/MF had lower costs (CAD $33,501 versus CAD $50,907) and higher quality-adjusted life-years (QALYs) (18.37 versus 18.06 QALYs) compared with SAL/FLU+TIO. Compared with SAL/FLU, IND/GLY/ MF had lower costs (CAD $33,408 versus CAD $36,577) and higher QALYs (19.33 versus 19.04 QALYs). IND/GLY/MF was the most cost-effective option in all scenarios tested. Conclusion: IND/GLY/MF was cost-effective at a willingness-to-pay threshold of CAD $50,000/QALY in patients with uncontrolled, moderate-to-severe asthma versus SAL/FLU +TIO and SAL/FLU in the base case and all scenarios tested. Keywords: moderate to severe asthma, indacaterol acetate, glycopyrronium bromide, mometasone furoate, cost-effectiveness, health care payer perspective, Canada, uncontrolled asthmaen_GB
dc.description.sponsorshipNovartis Pharma AGen_GB
dc.format.extent957-967
dc.identifier.citationVol. 13, pp. 957-967en_GB
dc.identifier.doihttps://doi.org/10.2147/ceor.s336915
dc.identifier.urihttp://hdl.handle.net/10871/128012
dc.language.isoenen_GB
dc.publisherDove Medical Pressen_GB
dc.rights© 2021 Mtibaa et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)en_GB
dc.titleCost-Effectiveness of once-daily, single-inhaler indacaterol acetate/ glycopyrronium bromide/ mometasone furoate in Patients with uncontrolled moderate-to-severe asthma in Canadaen_GB
dc.typeArticleen_GB
dc.date.available2021-12-03T13:51:47Z
dc.descriptionThis is the final version. Available from Dove Medical Press via the DOI in this record. en_GB
dc.descriptionData are available from the corresponding author upon reasonable request.en_GB
dc.identifier.eissn1178-6981
dc.identifier.journalClinicoEconomics and Outcomes Researchen_GB
dc.relation.ispartofClinicoEconomics and Outcomes Research, Volume 13
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/en_GB
dcterms.dateAccepted2021-11-11
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2021-12-03
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-12-03T13:49:19Z
refterms.versionFCDVoR
refterms.dateFOA2021-12-03T13:51:51Z
refterms.panelAen_GB
refterms.dateFirstOnline2021-12-03


Files in this item

Name:
CEOR-336915-cost-effectiveness ...
Size:
2.822Mb
Format:
PDF
Description:
Published version
View/Open

This item appears in the following Collection(s)

Show simple item record

© 2021 Mtibaa et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)
Except where otherwise noted, this item's licence is described as © 2021 Mtibaa et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)